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in Search of its Indications?We welcome the report of Sammartino et al on their
experience with remifentanil in preterm infants undergoing
laparotomy.1 Pain treatment is part of the quality of
neonatal care, both from an ethical and clinical outcome
perspective.2 Analgo-sedation in neonates is based on
assessment, administration of the appropriate analgesic
(pharmacokinetics) and reassessment (pharmacody-
namics).2 Remifentanil is metabolized by plasma esterases,
resulting in rapid predictable clearance, irrespective of
liver or renal function, and esterase activity is at an adult
level of activity at birth.1,3 Remifentanil has been used
mainly for short procedures such as endotracheal intuba-
tion, retinal laser surgery or percutaneous intravenous
central catheter placement.3 As clinical pharmacologists
and neonatologists interested in neonatal pain, we would
like to place remifentanil in a broader perspective of peri-
and postoperative care.
Although remifentanil pharmacokinetics are predict-
able, caregivers have to be aware that there are also
pharmacodynamic effects. Remifentanil-related analgo-
sedation disappears very soon after discontinuation.3 For
major surgery, such as laparotomy, anticipation and
replacement by another, longer-acting opioid or non-
opioid analgesic is needed, or the remifentanil infusion
should be prolonged. Further continuation will more
likely result in opioid-induced tolerance or hyperalgesia
because these phenomena are more common when
opioids with a short eliminination half-life are admini-
stered.
Shifts in neonatal clinical care towards less invasive
techniques have resulted in a shift in pharmacodynamic
endpoints (e.g., short-acting sedation).2 As a result of its
profile (esterase, short elimination half-life, intravenous),
remifentanil is a good option for analgo-sedation for
short-duration invasive procedures. In contrast, we
strongly advise also to consider the very same specificities
of remifentanil (i.e., very short-acting analgesia, toler-
ance and hyperalgesia), making this drug only poorly1875-9572/$36 Copyright ª 2012, Taiwan Pediatric Association. Publish
http://dx.doi.org/10.1016/j.pedneo.2012.10.001indicated after major surgery. Focused studies in
neonates on hyperalgesia, tolerance and neuro-
developmental outcome are needed. Until these data are
available, remifentanil in neonates remains a promising
compound in search of its indications, most likely proce-
dural analgo-sedation.Acknowledgments
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